77 research outputs found
Comptes rendus sur Dingler, Physik und Hypothese (1921)
Cette section contient les recensions que Rudolf Carnap, Moritz Schlick et Hermann Weyl ont donnĂ©es de l’ouvrage de Hugo Dingler : Physik und Hypothese. Versuch einer induktiven Wissenschaftslehre nebst einer krisÂtischen Analyse der Fundamente der Relativitätstheorie [Dingler 1921]. Elles sont traduites par Christophe Bouriau en collaboration avec Oliver Sehlaudt et Gerhard Heinzmann.In this section one finds reviews of Hugo Dingler’s Physik und Hypothese, Versuch einer induktiven Wissenschaftslehre nebst einer kristiÂschen Analyse der Fundamente der Relativitätstheorie [Dingler 1921], translaÂted by Christophe Bouriau in collaboration with Oliver Sehlaudt and Gerhard Heinzmann
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis
BACKGROUND: The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) versus ASC alone in aESCC. METHODS: We conducted a tri-center retrospective cohort study (n = 166) including patients with aESCC who had experienced disease progression on palliative first-line therapy. A propensity score model using inverse probability of treatment weighting (IPTW) was implemented for comparative efficacy analysis of overall survival (OS) in patients with second-line + ASC (n = 92, 55%) versus ASC alone (n = 74, 45%). RESULTS: The most frequent second-line regimens used were docetaxel (36%) and paclitaxel (18%). In unadjusted primary endpoint analysis, second-line + ASC was associated with significantly longer OS compared with ASC alone [hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.35–0.69, p < 0.0001]. However, patients in the second-line + ASC group were characterized by more favorable baseline features including a better Eastern Cooperative Oncology Group (ECOG) performance status, a longer first-line treatment duration and lower C-reactive protein levels. After rigorous adjusting for baseline confounders by re-weighting the data with the IPTW the favorable association between second-line and longer OS weakened but prevailed. The median OS was 6.1 months in the second-line + ASC group and 3.2 months in the ASC group, respectively (IPTW-adjusted HR = 0.40, 95% CI: 0.24–0.69, p = 0.001). Importantly, the benefit of second-line was consistent across several clinical subgroups, including patients with ECOG performance status ⩾1 and age ⩾65 years. The most common grade 3 or 4 adverse events associated with palliative second-line therapy were hematological toxicities. CONCLUSION: This real-world study supports the concept that systemic second-line therapy prolongs survival in patients with aESCC
- …